Four Researchers from The Rosalind and Morris Goodman Cancer Institute (GCI) have been awarded $4.4 million in federal health funding

The Canadian Institutes of Health Research (CIHR) released the results of their Fall 2023 Project Grant competition, with four GCI researchers being awarded $4.4 million in funding.

The national and provincial success rate for this project grant competition were 17% and 19% respectively. Notably, The GCI has surpassed both the national and provincial success rates, standing out with a remarkable 50% success rate.

The recent successes of our researchers underscore their commitment to pushing the boundaries of scientific inquiry and addressing pressing health challenges.

Learn more about the funded research projects:

1. William Muller: Identifying the molecular and environmental factors involved in promoting escape from breast cancer dormancy. Dr. Muller's project aims to unravel the intricate mechanisms underlying the escape from dormancy in breast cancer—a critical aspect influencing disease progression and recurrence.

2. Hanadi Sleiman in co-application with Morag Park: Targeting atypical B7 family checkpoints in poor-outcome triple-negative breast cancers. Dr. Sleiman and Dr. Park's collaborative endeavor focuses on targeting atypical immune checkpoint proteins for the development of novel immunotherapeutic strategies. Their work has profound implications for addressing the therapeutic challenges posed by triple-negative breast cancers.

3. Nahum Sonenberg: Control of Host mRNA Translation in Enterovirus Infection. Dr. Sonenberg's project delves into the intricate regulation of host mRNA translation in the context of enterovirus infection – a family of viruses which affect millions of people each year, with mild to severe outcomes.

4. Logan Walsh: Enhancing immunotherapy through the food-gut-axis in non-small cell lung cancer. Dr. Walsh's project explores the intricate nexus between the gut microbiome, diet, and immunotherapy outcomes in non-small cell lung cancer. By elucidating the role of the food-gut-axis in modulating anti-tumor immune responses, this research aims to inform therapeutic strategies and enhance treatment efficacy.

Back to top